Experience with ospemifene in patients with vulvar and vaginal atrophy and associated sexual dysfunction: case studies
The pathophysiological changes associated with hypoestrogenism of menopause, a condition known as genitourinary syndrome of menopause, are responsible for the hallmark symptoms of vulvovaginal atrophy (VVA), namely dyspareunia secondary to vaginal dryness. Many postmenopausal women with VVA find sex...
Main Authors: | Ana Rosa Jurado López, Francisca Molero Rodríguez |
---|---|
Format: | Article |
Language: | English |
Published: |
BioExcel Publishing Ltd
2020-07-01
|
Series: | Drugs in Context |
Subjects: | |
Online Access: | https://www.drugsincontext.com/experience-with-ospemifene-in-patients-with-vulvar-and-vaginal-atrophy-and-associated-sexual-dysfunction:-case-studies/ |
Similar Items
-
Ospemifene in the Management of Vulvar and Vaginal Atrophy: Focus on the Assessment of Patient Acceptability and Ease of Use
by: Cagnacci A, et al.
Published: (2020-01-01) -
Experience with ospemifene in patients with vulvar and vaginal atrophy and urinary incontinence: case studies
by: Zuramis Estrada Blanco, et al.
Published: (2020-07-01) -
Clinical update on the use of ospemifene in the treatment of severe symptomatic vulvar and vaginal atrophy
by: Palacios S, et al.
Published: (2016-10-01) -
Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause
by: Wurz GT, et al.
Published: (2014-11-01) -
Ospemifene for vulvar and vaginal atrophy: an overview
by: Santiago Palacios
Published: (2020-07-01)